This is a randomized, open-label phase 1/2a study designed to evaluate the pharmacokinetics, pharmacodynamics, and safety of AD-303A (topical formulation) and AD-3031 in male patients with androgenetic alopecia. The study aims to compare pharmacological characteristics and safety profiles to support dose selection for further clinical development.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
30
Seoul National University Hospital
Seoul, Seoul, South Korea
Maximum observed plasma concentration (Cmax) of dutasteride
The maximum observed plasma concentration (Cmax) of dutasteride following administration of the study drug.
Time frame: Up to Day14
Change from baseline in scalp dihydrotestosterone (DHT) concentration Description
Change from baseline in scalp tissue dihydrotestosterone (DHT) concentration measured following repeated administration of topical dutasteride.
Time frame: Baseline to Day 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.